Skip to main content
. Author manuscript; available in PMC: 2017 Jan 27.
Published in final edited form as: Vaccine. 2015 Dec 12;34(5):678–686. doi: 10.1016/j.vaccine.2015.11.074

Figure 4. M2e5x VLP-supplemented vaccination induces higher levels of antibodies against different virus strains.

Figure 4

Serum from immunized and naïve chickens (n=5 per group) were obtained 3 weeks after vaccination and inactivated purified virions analyzed by ELISA (A–E). Challenge viruses were examined using the HI method (F). (A) PSC24-24-specific antibody responses. (B) Gimje08-specific antibody responses. (C) VN015-specific antibody responses. (D) BC10-specific antibody responses. (E) 12AQ005-specific antibody responses. OD: optical density; rvPSC24-24 (one dose) + M2e5x VLPs: one dose of recombinant vaccine PSC24-24 containing 10 μg M2e5x VLPs; rvPSC24-24 (one dose): one dose of recombinant vaccine PSC24-24 alone; rvPSC24-24 (1/4 dose) + M2e5x VLPs: 1/4 dose of recombinant vaccine PSC24-24 containing 10 μg M2e5x VLPs; rvPSC24-24 (1/4 dose): 1/4 dose of recombinant vaccine PSC24-24 alone; naïve: control group injected with PBS; homo: homologous; hetero: heterologous.